Pharmaceuticals: Major
Argentine companies operating in the same pharmaceuticals: major industry
The list below has Argentine companies that operate under the same industry, pharmaceuticals: major. The list helps track their performance, income statement, and more. Sorted by any necessary metric, it can show the most expensive stocks of the industry such as ASTRAZENECA PLC CEDEAR EACH REP 0.5 ADR USD0.25 or those with the best price dynamics like GSK PLC CEDEAR EACH REPR 1/4 ADR (USD), thus assisting in designing strategies of any focus.
Symbol | Market cap | Price | Change % | Volume | Rel Volume | P/E | EPS dil TTM | EPS dil growth TTM YoY | Div yield % TTM | Sector | Analyst Rating |
|---|---|---|---|---|---|---|---|---|---|---|---|
 LLYELI LILLY AND COMPANY CEDEAR EACH 56 REP 1DR | 650.101 T ARS | 14994.500 ARS | +0.11% | 1.45 K | 0.60 | — | — | — | — | Health Technology | — |
| LLYDELI LILLY AND COMPANY CEDEAR EACH 56 REP 1 (USD) DR | 650.101 T ARS | 14.100 USD | +0.71% | 134 | 2.40 | — | — | — | — | Health Technology | — |
 DJNJ3JOHNSON & JOHNSON CEDEAR(REPR 6.95% BDS)DR | 316.394 T ARS | 1205.000 ARS | +0.42% | 9 | 0.00 | — | — | — | — | Health Technology | — |
| JNJJOHNSON & JOHNSON CEDEAR EACH 15 REP 1 ORD SHS DR | 316.115 T ARS | 10826.000 ARS | +1.18% | 9.409 K | 0.95 | 55.55 | 194.88 ARS | +348.94% | 0.85% | Health Technology | — |
| JNJDJOHNSON & JOHNSON CEDEAR EACH 15 REP 1 ORD SHS(USD) DR | 316.115 T ARS | 10.500 USD | +0.96% | 201 | 0.41 | 46.13 | 194.88 ARS | +19.44% | 0.85% | Health Technology | — |
 MRKMERCK & CO INC CEDEAR (5 REP 1 USD0.50)DR | 289.607 T ARS | 28164.000 ARS | +0.77% | 154 | 0.05 | — | — | — | — | Health Technology | — |
 ABBVABBVIE INC CEDEAR EACH 10 REPR 1 COMDR | 249.853 T ARS | 17341.500 ARS | +0.15% | 441 | 0.16 | 12.24 | 1417.30 ARS | +131.65% | 1.68% | Health Technology | — |
| ABBVDABBVIE INC CEDEAR EA 10 REP 1 COM(USD) DR | 249.853 T ARS | 18.000 USD | +5.88% | 11 | 0.72 | 10.87 | 1417.30 ARS | −38.37% | 1.68% | Health Technology | — |
 AZNASTRAZENECA PLC CEDEAR EACH REP 0.5 ADR USD0.25DR | 209.485 T ARS | 42040.000 ARS | +1.24% | 233 | 0.24 | 106.06 | 396.38 ARS | +306.81% | 1.02% | Health Technology | — |
| AZNDASTRAZENECA PLC CEDEAR EA RE 0.5 ADR (USD) DR | 209.485 T ARS | 41.800 USD | +7.18% | 4 | 0.74 | 90.29 | 396.38 ARS | +8.24% | 1.02% | Health Technology | — |
 NVSNOVARTIS AG CEDEAR EACH 4 REP 1DR | 174.514 T ARS | 27227.000 ARS | +1.10% | 49 | 0.40 | — | — | — | — | Health Technology | — |
 AMGNAMGEN INC CEDEAR EACH 30 REP 1DR | 145.5 T ARS | 11343.500 ARS | +3.06% | 1.652 K | 0.20 | — | — | — | — | Health Technology | — |
| AMGNDAMGEN INC CEDEAR EACH 30REPR 1 ORD USD0.0001 (USD) DR | 145.5 T ARS | 10.700 USD | −2.73% | 12 | 0.39 | — | — | — | — | Health Technology | — |
 PFEPFIZER INC CEDEAR EACH 4 REP 1 ORD USD0.05DR | 141.289 T ARS | 7646.000 ARS | +0.30% | 16.991 K | 0.62 | — | — | — | — | Health Technology | — |
| PFEDPFIZER INC CEDEAR 4 REP 1 ORD USD0.05(USD) DR | 141.289 T ARS | 7.300 USD | −0.68% | 1.227 K | 1.09 | — | — | — | — | Health Technology | — |
 GSKGSK PLC CEDEAR EACH REPR 1/4 ADRDR | 79.69 T ARS | 12058.500 ARS | +1.36% | 140 | 0.36 | 42.16 | 286.03 ARS | −2.78% | 1.25% | Health Technology | — |
| GSKDGSK PLC CEDEAR EACH REPR 1/4 ADR (USD) DR | 79.69 T ARS | 12.000 USD | +16.50% | 25 | 0.86 | 35.92 | 286.03 ARS | −74.13% | 1.25% | Health Technology | — |
 BMYBRISTOL-MYERS SQUIBB CO CEDEAR EACH 3 REP 1DR | 78.132 T ARS | 16176.000 ARS | +3.04% | 347 | 0.34 | — | — | — | — | Health Technology | — |
| BMYDBRISTOL-MYERS SQUIBB CO CEDEAR EACH 3 REP 1 DR | 78.132 T ARS | 15.050 USD | −2.27% | 2 | 0.39 | — | — | — | — | Health Technology | — |
 BIIBBIOGEN INC CEDEAR EACH 13 REP 1 COM USD0.0005DR | 28.235 T ARS | 18569.000 ARS | +1.56% | 179 | 0.13 | — | — | — | — | Health Technology | — |
 RICHLABORATORIOS RICHMOND SACIF | 74.049 B ARS | 898.500 ARS | −2.02% | 2.949 K | 0.42 | — | −46.54 ARS | — | 0.00% | Health Technology | — |
 ROSEINSTITUTO ROSENBUCH SA DE BIOLOGIA | 4.886 B ARS | 119.750 ARS | +4.36% | 9.041 K | 3.03 | — | — | — | 0.00% | Health Technology | — |